



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051	BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400 001
Security Symbol: IOLCP	Security Code: 524164

IOLCP/CGC/2020
10 February 2020

Subject: Outcome of the Board Meeting dated 10 February 2020 and submission of Financial Results for the quarter and nine months ended 31 December 2019.

Dear Sir,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 10th February, 2020 has inter alia considered and approved the Audited Financial Results for the Quarter and Nine Months ended 31 December 2019. Copy of said financial results along with unmodified Auditors Report thereon is enclosed herewith.


The above Financial Results are also available on the website of the Company i.e. www.iolcp.com.

The meeting of Board of Directors commenced at 12:00 PM and concluded at 04:55 PM.

This is for your information & record.

Thanking You,

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited


Abhay Raj Singh
AVP & Company Secretary





IOL CHEMICALS AND PHARMACEUTICALS LIMITED

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019

Rs. in Crore

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2019 (Audited)	30.09.2019 (Audited)	31.12.2018 (Unaudited)	31.12.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
	Income:						
I	Revenue from operations	511.25	448.96	478.29	1,453.01	1,263.04	1,685.33
II	Other Income	3.96	3.39	0.85	10.67	8.17	10.37
III	Total income (I+II)	515.21	452.35	479.14	1,463.68	1,271.21	1,695.70
	Expenses:						
IV	Cost of materials consumed	279.51	253.13	291.87	796.93	763.39	987.00
	Purchase of stock-in-trade	-	-	-	-	-	8.94
	Changes in inventories of finished goods and work-in-progress	9.78	(0.73)	(14.26)	25.62	75.85	51.31
	Employee benefits expense	24.06	24.08	22.22	72.13	59.22	78.43
	Finance costs	3.76	6.09	12.85	18.17	42.59	51.42
	Depreciation and amortization expense	8.94	8.84	8.38	26.37	24.46	32.45
	Other expenses	38.40	39.56	42.95	121.30	112.07	150.00
	Total Expenses (IV)	364.45	330.97	364.01	1,060.52	1,077.58	1,359.55
V	Profit before exceptional items and tax (III-IV)	150.76	121.38	115.13	403.16	193.63	336.15
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V-VI)	150.76	121.38	115.13	403.16	193.63	336.15
VIII	Tax Expense:						
	Current tax	50.01	34.76	24.80	129.39	41.71	71.96
	Tax adjustment for earlier years	1.10	-	-	1.10	-	-
	Deferred tax	1.64	(1.08)	8.09	1.64	16.87	27.49
	Total tax expense	52.75	33.68	32.89	132.13	58.58	99.45
IX	Profit for the period (VII-VIII)	98.01	87.70	82.24	271.03	135.05	236.70
X	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss						
	Remeasurement of Defined benefit obligation	0.15	(2.13)	-	(1.98)	-	(2.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.06)	0.75	-	0.69	-	0.75
XI	Total Comprehensive Income for the period (IX+X)	98.10	86.32	82.24	269.74	135.05	235.30
XII	Paid-up equity share capital (Face value Rs.10/- per share)	56.89	56.89	56.21	56.89	56.21	56.89
XIII	Earning per share (of Rs.10/- each) (for continuing and discontinued operations) (not annualised except for the year ended 31.03.2019)						
	Basic (Rs.)	17.22	15.42	14.63	47.64	24.03	42.11
	Diluted (Rs.)	17.22	15.42	14.63	47.64	24.03	42.11



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES


Sr.No.	Particulars	Quarter Ended			Nine Months Ended		Rs. in Crore
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	Year Ended
		(Audited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment Revenue (Net sale/income)						
	- Chemicals	193.87	163.81	217.88	555.04	571.20	765.34
	- Drugs	326.48	293.80	314.68	928.95	830.94	1,120.78
	- Unallocated	2.41	2.52	3.81	6.37	16.89	18.44
	Total	522.76	460.13	536.37	1,490.36	1,419.03	1,904.56
	Less : Inter segment revenue	7.55	7.78	57.23	26.68	147.82	208.86
	Net sales/income from operations	515.21	452.35	479.14	1,463.68	1,271.21	1,695.70
2	Segment Results Profit before tax and interest from each segment)						
	- Chemicals	9.63	5.54	6.45	22.70	13.89	26.51
	- Drugs	143.87	120.42	119.91	395.55	217.49	357.92
	Total	153.50	125.96	126.36	418.25	231.38	384.43
	Less: Interest	3.76	6.09	12.85	18.17	42.59	51.42
	Add: Other un-allocable income net off un-allocable expenditure	1.02	1.51	1.62	3.08	4.84	3.14
	Total Profit before tax & Extraordinary items	150.76	121.38	115.13	403.16	193.63	336.15
3	Segment Assets						
	- Chemicals	340.92	323.94	312.24	340.92	312.24	304.64
	- Drugs	607.20	548.52	533.12	607.20	533.12	550.65
	- Unallocated	186.10	154.10	53.53	186.10	53.53	86.59
	Total Assets	1,134.22	1,026.56	898.89	1,134.22	898.89	941.88
4	Segment Liabilities						
	- Chemicals	122.20	119.25	117.87	122.20	117.87	74.83
	- Drugs	75.97	87.02	63.87	75.97	63.87	75.53
	- Unallocated	191.97	174.31	366.37	191.97	366.37	317.18
	Total Liabilities	390.14	380.58	548.11	390.14	548.11	467.54


NOTES:

- The above results have been reviewed by the Audit & Risk Management Committee and thereafter approved by the Board of Directors in their respective meetings held on 10 February 2020.
- The financial results for the quarter / nine months ended 31 December 2019 have been audited by the Statutory Auditors and they have expressed their unmodified reports thereon, whereas the results for the corresponding quarter / nine months period ended 31 December 2018 were subjected to limited review by the auditors.
- The Company has adopted Ind AS 116 'Leases' effective 01 April 2019 (transition date), and applied the standard to its Leases using the modified retrospective approach. Accordingly, the comparatives have not been retrospectively adjusted. This has resulted in recognizing a Right-of-use assets and corresponding Lease Liability of Rs.4.16 Crore and its application did not have any material impact on the financial results of the Company.
- The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

Place: Ludhiana
Date: 10 February 2020

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited


Vijay Garg
Managing Director
DIN: 06510248



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

**INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF THE INTERIM
FINANCIAL RESULTS**

To
The Board of Directors of
IOL Chemicals and Pharmaceuticals Ltd.

Opinion

We have audited the accompanying Financial Results of IOL Chemicals and Pharmaceuticals Ltd. CIN-(L24116PB1986PLC007030) ("the Company"), for the quarter and nine months period ended December 31, 2019 ("the Financial Results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Financial Results:

- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (ii) gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and nine months period ended December 31, 2019.

Basis for Opinion

We conducted our audit in accordance with the standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Interim Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the interim financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit of evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management Responsibilities for the Interim Financial Results

These Financial Results, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited interim financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the interim financial results that give a true and fair view



of the net profit and other comprehensive income and other financial information in accordance with Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the interim financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the interim financial results, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor’s Responsibilities for the Audit of the Interim Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these interim financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the interim financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the interim financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the interim financial results, including the disclosures, and whether the financial results present the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the interim financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the interim financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For and on behalf of
Ashwani & Associates
Chartered Accountants

Firm Registration Number: 000497N

by the hand of


 Aditya Kumar
 Partner

Membership No.: 506955

UDIN: 20506955AAAABW9770

Place: Ludhiana

Dated: February 10, 2020